MoonLake Faces Expanding Securities Suits as Lead-Plaintiff Deadline Nears

Overview

• Bleichmar Fonti & Auld filed a case in the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, No. 1:25-cv-08612.
• Complaints assert violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 tied to statements about sonelokimab.
• Plaintiffs allege MoonLake overstated SLK's Nanobody advantages over BIMZELX and that both target IL-17A and IL-17F without a superior clinical benefit.
• MoonLake's late-September Phase 3 VELA disclosure drew analyst criticism as a "disastrous" result, and MLTX shares dropped nearly 90% in one trading day.
• Multiple firms, including Hagens Berman, Schall, DJS Law Group, and Frank R. Cruz, are recruiting investors, with one firm seeking whistleblower tips as the class remains uncertified.